• PETNET Solutions

    Delivering, Expanding, Advancing

PETNET Solutions Australia

PETNET Solutions Australia was opened by Senator the Hon Kim Carr – Minister for Innovation, Industry, Science and Research on 6th August 2009. PETNET Solutions Australia is a subsidiary of ANSTO (Australian Nuclear Science and Technology Organisation) and a franchise of Siemens USA.

In Australia, the state-of-the-art PET radiopharmaceutical production facility built in Sydney’s south, consists of two Siemens cyclotrons which produce the short-lived radiopharmaceutical 18F FDG (fluorodeoxyglucose) used in PET scanning and supplied to PET facilities. 18F synthesised isotopes have a half life of 110 minutes which is enough time to manufacture, deliver and scan patients so that diagnosis and treatment programs can be completed and implemented for better patient outcomes.

In Australia PET/CT is predominantly used in the diagnosis of numerous cancers and is becoming integral in the working up of patient cases in hospital MDT (multi disciplinary teams) which has become the preferred format for case discussions within the Hospital environment.

As molecular imaging evolves, PETNET Solutions Australia delivers products and services that expand the value of PET to providers, referring medical specialists and patients. PETNET Solutions is delivering, expanding, and advancing the science of molecular imaging.

In Australia, manufacture of all radiopharmaceuticals is regulated by the Therapeutic Goods Administration (TGA). PETNET Solutions currently holds a licence to manufacture Therapeutic Goods issued by the TGA and manufactures under Good Manufacturing Practice (GMP) conditions.

Additionally, patients can be assured of the quality of PETNET products as PETNET is the only commercial supplier in Australia to have obtained an Aust R registration for 18F FDG (fludeoxyglucose). Patients can be confident that product quality and purity is maintained right from production to labelled expiration time as the products comply with all relevant Commonwealth and State regulations.

Delivering – State of the art and quality radiopharmaceuticals

Expanding – Market usage and accessibility to quality product
Advancing – Knowledge and medical know how

To improve patient outcomes